Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
=== Acute health effects === Capsaicin is a strong irritant requiring proper protective goggles, respirators, and proper hazardous material-handling procedures. Capsaicin takes effect upon skin contact (irritant, sensitizer), eye contact (irritant), ingestion, and inhalation (lung irritant, lung sensitizer). The LD50 in mice is 47.2 mg/kg. Painful exposures to capsaicin-containing peppers are among the most common plant-related exposures presented to poison centers. They cause burning or stinging pain to the skin and, if ingested in large amounts by adults or small amounts by children, can produce nausea, vomiting, abdominal pain, and burning diarrhea. Eye exposure produces intense tearing, pain, conjunctivitis, and blepharospasm.
Serotonin syndrome: Triggered by serotonergic drugs (ex: SSRI); features include delirium, hyperreflexia, myoclonus, GI symptoms (N/V/D), autonomic instability, hyperthermia, and rigidity. Malignant hyperthermia: A hereditary disorder of skeletal muscle, triggered by anesthetics or muscle relaxants like succinylcholine.; associated with metabolic acidosis, hyperkalemia, and arrhythmias. Akinetic mutism is a neurological disorder associated with structural damage in a variety of brain, it is characterized by immobility and mutism but intact awareness; lacks echolalia/echopraxia. Furthermore, it is unresponsive to benzodiazepines. Patients may present with apathy, and may seem indifferent to pain, hunger, or thirst. Selective mutism has an anxious etiology but has also been associated with personality disorders. Patients with this disorder fail to speak with some individuals but will speak with others. Likewise, they may refuse to speak in certain situations; in another word it is anxiety-driven; speech restriction limited to certain contexts, without catatonic signs. for example, a child who refuses to speak at school but is conversational at home. This disorder is distinguished from catatonia by the absence of any other signs/symptoms. Nonconvulsive status epilepticus is seizure activity with no accompanying tonic-clonic movements. It can present with stupor, similar to catatonia, and they both respond to benzodiazepines. Nonconvulsive status epilepticus is diagnosed by the presence of seizure activity seen on electroencephalogram (EEG).
=== Television === Scénarios sur la drogue (2000) – directed by Guillaume Canet and Jean-Christophe Pagnac (episode "Avalanche") Nana (2001) – directed by Édouard Molinaro The Private Life of Samuel Pepys (2003) – directed by Oliver Parker Gossip Girl (2010) – directed by Mark Piznarski and starring Doillon as herself
Sources: en.wikipedia.org
Impetigo herpetiformis Intrahepatic cholestasis of pregnancy (cholestasis of pregnancy, jaundice of pregnancy, obstetric cholestasis, prurigo gravidarum) Linea nigra Pemphigoid gestationis (gestational pemphigoid, herpes gestationis) Prurigo gestationis (Besnier prurigo, early-onset prurigo of pregnancy, linear IgM dermatosis of pregnancy, papular dermatitis of pregnancy, prurigo of pregnancy, Spangler's papular dermatitis of pregnancy) Pruritic folliculitis of pregnancy Pruritic urticarial papules and plaques of pregnancy (late-onset prurigo of pregnancy, polymorphic eruption of pregnancy, PUPPP syndrome, toxemic rash of pregnancy, toxic erythema of pregnancy) Striae gravidarum
== Lexicology == The Latin term impotentia coeundi describes simple inability to insert the penis into the vagina; it is now mostly replaced by more precise terms, such as erectile dysfunction (ED). The study of ED within medicine is covered by andrology, a sub-field within urology. Research indicates that ED is common, and it is suggested that approximately 40% of males experience symptoms compatible with ED, at least occasionally. The condition is also on occasion called phallic impotence. Its antonym, or opposite condition, is priapism.
===== U.S. Congress ===== In the aftermath of the recall, there was a call from consumers for an investigation into Menu Foods reaction to the poisonings, and the federal government's stand on pet food safety and quality control and the FDA's response to the recall. On 1 April 2007, Senator Dick Durbin (D – Illinois) called on the FDA to "account for weak links in the pet food inspection system." Earlier in the week, Representative Rosa DeLauro (D – Connecticut) asked for an analysis of the FDA's oversight of pet food manufacturing facilities and a report of actions taken since the recall. On 6 April 2007, Senator Durbin criticized the federal inspection process for both human and pet food and called for the hearings on the matter. According to the Los Angeles Times who interviewed Durbin 8 April, Durbin said he would like to see the FDA set national standards and inspection rules for pet food manufacturing facilities, and to see "federal law changed to allow the FDA to order a recall of food intended for human or pet consumption rather than rely on companies to do it voluntarily." Durbin was working with Senator Herb Kohl (D – Wisconsin), the Chairman of the United States Senate Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies. Senator Kohl initiated hearings in the Senate Appropriations Subcommittee along with Senator Durbin and Senator Bob Bennett (R – Utah). Senator Robert Byrd (D – West Virginia), from the United States Senate Committee on Appropriations was there as well.
=== Disadvantages === Flame ionization detectors cannot detect inorganic substances and some highly oxygenated or functionalized species like infrared and laser technology can. In some systems, CO and CO2 can be detected in the FID using a methanizer, which is a bed of Ni catalyst that reduces CO and CO2 to methane, which can be in turn detected by the FID. The methanizer is limited by its inability to reduce compounds other than CO and CO2 and its tendency to be poisoned by a number of chemicals commonly found in gas chromatography effluents. Another important disadvantage is that the FID flame oxidizes all oxidizable compounds that pass through it; all hydrocarbons and oxygenates are oxidized to carbon dioxide and water and other heteroatoms are oxidized according to thermodynamics. For this reason, FIDs tend to be the last in a detector train and also cannot be used for preparatory work.
Sources: en.wikipedia.org
=== Current use === In the 21st century, the high price of nickel has led to some replacement of the metal in coins around the world. Coins still made with nickel alloys include one- and two-euro coins, 5¢, 10¢, 25¢, 50¢, and $1 U.S. coins, and 20p, 50p, £1, and £2 UK coins. From 2012 on the nickel-alloy used for 5p and 10p UK coins was replaced with nickel-plated steel. This ignited a public controversy regarding the problems of people with nickel allergy.
The reason is simple: no recognition, no normalisation. Just boycott, divestment and sanctions, until the apartheid state is defeated. I never debate with Israelis nor speak to their media. If they want to speak about Palestine – the address is the PLO. Galloway later said on his Twitter feed that he had been "misled", writing that "Christ Church never informed us that the debate would be with an Israeli. Simple." The organiser, Mahmood Naji, denied Galloway's allegations in an open letter, explaining: "At no point during my email exchange with Mr Galloway's secretary was Eylon's nationality ever brought up or mentioned ... nor do I expect to have to tell the speaker what his opponent's nationality is." Galloway's behaviour was criticised by Julian Huppert, the Liberal Democrat MP for Cambridge, and The Times. The Palestinian Boycott, Divestment and Sanctions (BDS) National Committee subsequently released a statement indicating that, while it does support a "boycott of Israel", the campaign rejects boycotting an individual "because she or he happens to be Israeli or because they express certain views." In a debate at The Oxford Union the following October, Galloway compared the support of debating Israeli Zionists with that of supporting South African apartheid. Referring indirectly to his encounter with Aslan-Levy, Galloway said that he had worked with Jewish anti-apartheid activists in South Africa, adding "So Jews don't have to be on the side of apartheid".
== History == The mdx mouse was first described in 1984 by Bulfield et al. in a colony of C57BL/10ScSn mice, showing elevated muscle creatine kinase (CK) and histological lesions characteristic of muscular dystrophy. In 1989, Sicinski et al. identified the precise mutation: a C-to-T transition (nonsense point mutation) in exon 23 of the Dmd gene, creating a premature stop codon and abolishing full-length dystrophin expression. This makes mdx mice a key model for Duchenne muscular dystrophy.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.